Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
